The group aims to discover and validate new biomarkers, as well as develop clinical models that are relevant in vitro and in vivo, emphasising the identification of predictive markers, with the ultimate goal of improving the diagnosis and prognosis of these types of cancer.

The group takes part in international multidisciplinary consortia and collaborative research programmes. It also works with academic groups and pharmaceutical companies on the validation of repositioning drugs or candidate drugs, while extending collaboration with other VHIO teams.

Visit the research group’s page


Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.